Alternatives to Sylentis
Sylentis is a Biotech tool: ophthalmic pharmaceutical company developing novel treatments for ocular diseases. Here are the 60 closest alternatives, compared on pricing, features and what real users say.
The 20 closest Biotech companies to Sylentis
- Website
Rocket Pharmaceuticals57BiotechnologyCranbury, USA$382.9MA biotechnology company developing genetic therapies for rare disorders.
- Website
Editas Medicine42BiotechCambridge, United States$210.0MA clinical-stage biotechnology company developing transformative genome editing medicines for serious diseases.
- Website
Adaptive Biotechnologies69BiotechSeattle, United States$300.0MLeveraging the adaptive immune system to diagnose and treat disease.
- Website
BeiGene65BiotechCambridge, United States$358.0MA global oncology company developing and commercializing innovative cancer treatments.
- Website
Synthace62BiotechLondon, United Kingdom$60.6MSynthace provides a no-code cloud platform for life sciences R&D, enabling scientists to automate experimentation and insight sharing.
- Website
Cue Biopharma, .62BiotechBoston, United States$10.0MDeveloping engineered biologics to harness the immune system for disease treatment.
- Website LELexeo Therapeutics61BiotechNew York City, United States$495.0M
Clinical-stage genetic medicine company developing AAV-mediated treatments for cardiovascular and Alzheimer's diseases.
- Website
ImCheck Therapeutics60BiotechMarseille, France$164.0MImCheck Therapeutics is a clinical-stage immuno-oncology company developing novel antibody therapies.
- Website
Caris Life Sciences59BiotechIrving, United States$700.0MCaris Life Sciences is a leading innovator in molecular science, offering precision medicine solutions for cancer patients through advanced molecular profiling.
- Website
Guardant Health57BiotechRedwood City, United States$900.0MGuardant Health is a precision oncology company that develops and commercializes liquid biopsy tests for cancer detection, recurrence monitoring, and treatment selection.
- Website
Harmony Biosciences Holdings57BiotechPlymouth Meeting, United States$400.5MBiopharmaceutical company focused on developing and commercializing innovative treatments for rare neurological disorders.
- Website
Amicus Therapeutics57BiotechPhiladelphia, United States$200.0MBiotechnology company focused on developing treatments for rare metabolic diseases.
- Website
Cellcolabs55BiotechTel Aviv, Israel$15.5MAI-powered platform for personalized cell therapy development and manufacturing.
- Website
Ultragenyx55BiotechNovato, United States$100.0MBiopharmaceutical company developing novel therapies for rare and ultra-rare genetic diseases.
- Website PRProNAi Therapeutics55Biotech$115.8M
A clinical-stage oncology company developing DNA interference (DNAi) based cancer therapies.
- Website
Alector55BiotechSouth San Francisco, United States$162.5MBiotechnology company developing immuno-neurology therapies for neurodegenerative diseases.
- Website
Regenxbio55BiotechRockville, United States$180.0MClinical-stage biotech company developing AAV gene therapies for rare and retinal diseases.
- Website
Tenaya Therapeutics55BiotechSouth San Francisco, United States$158.5MBiotechnology company developing gene therapies and regenerative medicine for heart disease.
- Website
BioLife Solutions54BiotechBothell, United States$96.4MDevelops and markets bioproduction tools for cell and gene therapy manufacturing and distribution.
- Website
ProteinQure54BiotechCambridge, United States$15.6MBiotech company using AI and computational platforms to design novel peptide therapeutics.
Showing the 20 closest matches. See the rest on the Sylentis profile.